article
Could metabo-oncology be the treatment modality of the future?
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
List view / Grid view
Therapeutics
news
Inhibiting the GLS1 enzyme could improve numerous age-associated disorders, finds study
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
news
Researchers identify how Zika infects foetuses and a potential drug to prevent it
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
news
Thapsigargin could be used as antiviral to treat COVID-19, study shows
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://drug.russellpublishing.co.uk/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati-720x500.jpg)
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://drug.russellpublishing.co.uk/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati.jpg)
news
HIV drugs could be repurposed to prevent the onset of macular degeneration
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
Targeting the HCF-1 protein causes cancerous cells to self-destruct
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
news
Melatonin could act as barrier against SARS-CoV-2 infection
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
news
Novel compound named BC1618 could serve as new diabetes drug
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
Two novel molecules to potentially combat asthma discovered
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
news
In vitro model could aid the development of fatty liver disease treatments
The patient-derived model of non-alcoholic fatty liver disease (NAFLD) accurately reproduced the complex human metabolic pathways involved in the development of the disease.
news
NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
